Business Context and Reporting Period
Company: Apollomics Inc. (Nasdaq: APLM)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Apollomics is a clinical-stage biotechnology company focused on oncology therapies. Its lead product candidate is vebreltinib (APL-101), a c-Met inhibitor. The company operates as a Cayman Islands holding company with subsidiaries in the U.S., China, Australia, and Hong Kong. In September 2025, the company underwent a complete leadership transition and reversed a planned wind-down following a $4.1 million PIPE financing.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $8.5 million | $0 |
| Net Loss | $(10.9) million | $(53.9) million |
| Operating Cash Flow | $(10.4) million | $(28.7) million |
| Cash and Cash Equivalents (Year-End) | $3.3 million | $9.8 million |
| Accumulated Deficit | $(711.8) million | $(700.8) million |
| Intangible Asset Impairment | $(1.7) million | $(13.0) million |
Note: Revenue in 2025 was derived from a licensing agreement with LaunXP International. The company remains pre-commercial with no product sales revenue.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $8.5 million in revenue in 2025 from a licensing deal with LaunXP, compared to zero revenue in 2024. This represents a significant shift from a purely burn-rate model to generating licensing income.
- Loss Reduction: Net loss decreased by approximately 80% year-over-year (from $53.9 million to $10.9 million), driven by aggressive cost-cutting, staff reductions, and the termination of several development programs.
- Asset Impairment: Impairment charges dropped significantly from $13.0 million in 2024 to $1.7 million in 2025. The 2024 charge was largely due to the termination of the uproleselan program following negative Phase 3 results from a partner.
- Liquidity Position: Cash reserves declined by roughly $6.5 million during the year, leaving the company with $3.3 million as of year-end.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has determined that substantial doubt exists regarding the company's ability to continue as a going concern. As of December 31, 2025, cash resources were insufficient to meet obligations through April 30, 2027, even accounting for an expected $2.3 million receivable from LaunXP. The financial statements are prepared on a going concern basis without adjustments for potential liquidation.
Subsequent Events & Liquidity Support
- Bridge Loan: On March 30, 2026, the Chairman and CEO, Mr. Hung-Wen (Howard) Chen, provided a $2.0 million unsecured convertible bridge loan to support operations.
- PIPE Financing: In September 2025, the company raised $4.1 million via a private placement (PIPE) to reverse wind-down plans.
Key Risks and Contingencies
- Legal Proceedings:
- Medpace Litigation: Active litigation with CRO Medpace, Inc. regarding unpaid fees. Medpace claims ~$2.3 million; Apollomics has filed a counterclaim seeking >$2.0 million for alleged overcharges and misappropriation. No provision has been recorded as an outflow is not deemed probable.
- TWVC Settlement: Settled litigation with minority investors for $5.0 million plus ~$0.9 million in legal fees. $4.0 million remains unpaid as of year-end.
- Regulatory & Development: The U.S. NDA filing for vebreltinib for NSCLC with MET exon 14 skipping has been indefinitely deferred. The company is pivoting focus to NSCLC with c-Met amplification. Enrollment challenges persist due to non-standard genetic testing requirements.
- Intellectual Property: Third-party "Structure Patents" and "General Method Patents" expire in late 2026. While the company does not anticipate commercializing before expiration, potential licensing disputes remain a risk.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.3 million year-end cash balance plus the $2.0 million bridge loan against the company's burn rate and the $4.0 million legal settlement obligation due in 2026.
- LaunXP Receivable: Confirm the collection status of the $2.3 million outstanding receivable from LaunXP, which is critical to the company's liquidity assessment.
- Medpace Litigation Outcome: Monitor the resolution of the Medpace dispute, as an unfavorable outcome could require immediate cash outflows exceeding current reserves.
- Capital Raising: Assess the feasibility of the company's plan to raise additional equity or debt capital, given the current market conditions for pre-revenue biotechs.
- Leadership Stability: Evaluate the execution capability of the new management team appointed in September 2025 following the complete turnover of the previous executive leadership.